Last reviewed · How we verify
autologous EBV specific CTLs
At a glance
| Generic name | autologous EBV specific CTLs |
|---|---|
| Also known as | EBV specific CTLs |
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE (PHASE1)
- EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma (PHASE1)
- T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL (PHASE1)
- Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients (PHASE1)
- Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) (PHASE1)
- In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies (PHASE1)
- Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant (EARLY_PHASE1)
- A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |